Phase Ib/IIa Clinical Study of ACC017 Tablets
Phase 1
Recruiting
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: ACC017+FTC/TAFDrug: Placebo
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jiangsu Aidea Pharmaceutical Co., Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT06719310
- Locations
- 🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, China
Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- Healthy Adult Participants
- Interventions
- Drug: ACC017 tablets
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Jiangsu Aidea Pharmaceutical Co., Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT06278389
- Locations
- 🇨🇳
Beijing Ditan Hospital Capital Medical University, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath